Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automati...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

ViktorSinclair May. 4 at 2:12 PM

$SCYX Still no SEC confirmation re: nas compliance. Has anyone heard anything official? I know it takes about 3-5 days after we met it and I believe we have... but still nothing. we should hear something today or tomorrow OR there is a problem

0 · Reply

SnapCrackleStop May. 3 at 1:50 PM

$SCYX SCY-770 has Orphan Drug Designation for ADPKD, an indication with clear regulatory path and well-defined endpoints including an FDA-endorsed surrogate endpoint for accelerated approval. $$$

0 · Reply

LemuelPitkin May. 2 at 6:06 PM

$SCYX SCY-770 Will be the next GLP-1 type breakthrough drug blockbuster. So much of our metabolism is based on food scarcity. Now take food scarcity off the table! This AMPK activator fits into this context. There is no negative trade-off so long as we don't have food scarcity. End result longer life. AMPK activators like SCY-770 (PXL-770) pharmacologically mimic a low-energy/fasted state in an environment of caloric abundance (modern diets with frequent eating and food surplus). This creates several metabolic trade-offs: clear benefits for metabolic diseases, but potential downsides from overriding normal fed-state physiology.

1 · Reply

LemuelPitkin May. 2 at 5:52 PM

$SCYX Remember that I said it here first: Pxl-770/SCY-770 may become the key preventive treatment for Alzheimer' disease and insulin resistant diabetes. I base this on SCY-770s metabolic effects and anti-inflammatory effects. Write it down. You heard it here first.

1 · Reply

SnapCrackleStop May. 2 at 1:01 AM

$SCYX Read this S3 filing closely….., these entities all bought the stock back on march 31 to enable SCYX to make their acquisition. They can’t sell the stock at any point until SCYX registers that stock by filing an S3 which they did today. SO those who are listed on the S3 are now free to sell their stock whenever they want or never. Since they just made this investment a month ago at current prices it’s highly unlikely they intend to sell their stock anywhere around the current price. We are watching a scripted play. Opening Acts just completed. Hoping for a happy ending. $$$

1 · Reply

DataJim May. 1 at 10:11 PM

$SCYX Strange After Hours drop. Not filing was a nothing burger, we already knew all that.

2 · Reply

LemuelPitkin May. 1 at 8:25 PM

$SCYX think about this. Of the two other drugs we have to develop, only Scy-770 is free of commitments other than what is in the agreement in terms of milestone payments. Meanwhile, Scy-247 is granted to GSK by the right of first refusal. But GSK has proven itself to be a terrible partner. This leads me to speculate that all of the effort going forward will be into scy 770. And that's a great choice! It's a drug with multiple uses. Besides autosomal dominant polycystic kidney disease. So I will not be surprised to see that clinical advancement occurs in in SCY-770 while SCY-247 is put on the slow back burner. The only way I see that changing is if GSK does an honest job of putting brexafemme back into the marketplace/ pharmacies

0 · Reply

pjinvestmentco Apr. 30 at 1:23 PM

$SCYX reverse stock spilt will happen with you or without you at this point who really cares

2 · Reply

DataJim Apr. 29 at 10:14 PM

$SCYX Attention swing traders, this is a pretty good entry. The offering was at $.92 in the warrants are at $1.20. This is likely to be in that range for quite a while.

0 · Reply

btm811 Apr. 29 at 3:05 PM

$SCYX some day I hope we get a Netflix documentary about how big of a fucking scam this company is and how they treat their investors, would make for an entertaining watch at the very least

1 · Reply

SCYNEXIS Transcript: M&A announcement

Mar 31, 2026, 7:06 AM EDT - 4 weeks ago

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

Mar 31, 2026, 6:45 AM EDT - 4 weeks ago

SCYNEXIS Announces $40.0 Million Private Placement

Mar 31, 2026, 6:40 AM EDT - 4 weeks ago

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mar 4, 2026, 4:20 PM EST - 2 months ago

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 26, 2026, 8:23 AM EST - 2 months ago

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

Feb 17, 2026, 8:00 AM EST - 2 months ago

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CRVO

Dec 22, 2025, 8:00 AM EST - 4 months ago

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Nov 19, 2025, 7:00 AM EST - 5 months ago

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Nov 5, 2025, 4:20 PM EST - 6 months ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 15, 2025, 8:00 AM EDT - 7 months ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Sep 4, 2025, 8:30 AM EDT - 8 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Aug 13, 2025, 4:30 PM EDT - 9 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 28, 2025, 8:30 AM EDT - 1 year ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Mar 12, 2025, 5:08 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Sep 11, 2024, 10:00 AM EDT - 1 year ago

SCYNEXIS Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 8, 2024, 4:30 PM EDT - 2 years ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:05 PM EDT - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 9, 2024, 4:05 PM EDT - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Mar 28, 2024, 4:01 PM EDT - 2 years ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 7, 2024, 11:00 AM EST - 2 years ago

SCYNEXIS Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 29, 2024, 5:15 PM EST - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 8, 2024, 4:00 AM EST - 2 years ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 5, 2024, 8:30 AM EST - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 4, 2024, 7:00 AM EST - 2 years ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 2 years ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 28, 2023, 9:00 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 22, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:15 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 30, 2023, 8:30 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 29, 2023, 7:50 PM EST - 2 years ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 2 years ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

ViktorSinclair May. 4 at 2:12 PM

0 · Reply

SnapCrackleStop May. 3 at 1:50 PM

$SCYX SCY-770 has Orphan Drug Designation for ADPKD, an indication with clear regulatory path and well-defined endpoints including an FDA-endorsed surrogate endpoint for accelerated approval. $$$

0 · Reply

LemuelPitkin May. 2 at 6:06 PM

1 · Reply

LemuelPitkin May. 2 at 5:52 PM

1 · Reply

SnapCrackleStop May. 2 at 1:01 AM

1 · Reply

DataJim May. 1 at 10:11 PM

$SCYX Strange After Hours drop. Not filing was a nothing burger, we already knew all that.

2 · Reply

LemuelPitkin May. 1 at 8:25 PM

0 · Reply

pjinvestmentco Apr. 30 at 1:23 PM

$SCYX reverse stock spilt will happen with you or without you at this point who really cares

2 · Reply

DataJim Apr. 29 at 10:14 PM

$SCYX Attention swing traders, this is a pretty good entry. The offering was at $.92 in the warrants are at $1.20. This is likely to be in that range for quite a while.

0 · Reply

btm811 Apr. 29 at 3:05 PM

$SCYX some day I hope we get a Netflix documentary about how big of a fucking scam this company is and how they treat their investors, would make for an entertaining watch at the very least

1 · Reply

intheriver Apr. 29 at 2:30 PM

$SCYX Also, I will be looking closely at their analysis to support the additional executive compensation. My first instinct was to vote against it. But, they provide analysis and I’ll review to see if it’s fair. A high bar needs to be set for management given their past disappointments. New leadership might be what this company needs to unlock the value.

0 · Reply

intheriver Apr. 29 at 2:04 PM

$SCYX As stated in their rationale for the May 19th meeting: “Without the Reverse Stock Split, the Company may be unable to regain compliance with Nasdaq’s minimum bid price listing requirements by June 15, 2026,” If they have receive a letter stating they are compliant, but do not notify its shareholders, they will create legal risks. This is a significant event. They need to disclose any update on compliance which would impact how one votes. Obviously, the June 15th date would no longer be relevant if they regained compliance. It is possible that Nasdaq has put a more strict requirement on SCYX (rare). That too would be significant, given they stated the 10-day rule. I await the news. Latest I could imagine an update would be Monday. But typically, the compliance letter happens soon after compliance with a 1 to 3 day reporting requirement.

1 · Reply

intheriver Apr. 29 at 12:58 PM

$SCYX I don’t recall all specifics, but SCYX will need to report on compliance since it is a significant event. I believe they have 2 days from receiving the compliance letter to report in an 8k. Recall they specifically filed an 8k when they were out of compliance, stating 10 consecutive days above $1 would be needed to comply (just standard compliance). They’ve done that. Now we wait for the announcement. Maybe we recieve other good news in the same announcement.

1 · Reply

ImadogImaMut Apr. 29 at 12:02 PM

$SCYX Has anyone considered that this may be headed towards a splitting of assets where GSK gets 178 and 247 and David gets left with a company to run based upon the one new promising Kidney franchise 🍀

0 · Reply

SnapCrackleStop Apr. 28 at 3:32 PM

$SCYX Contemplating the R/S. Ok. I agree. Reverse if you can attract more institutional investors. So much potential here but A $1 SP does prohibit some funds from acquiring shares. If they reduce share count it has little to no impact on business. Just simply puts lipstick on this pig. 🐽 $$$

1 · Reply

ImadogImaMut Apr. 28 at 9:56 AM

$SCYX Really a tell to me : No PR to even say regained compliance .I think we don’t make it to earnings Calling this one BUY OUT 4.60!/share Thanks for coming out Nothing left to see bye 👋 I’m going to protect this duck who has taken over this road OMG 🫣

1 · Reply

pjinvestmentco Apr. 27 at 9:23 PM

$SCYX new filing shows they are still doing the reverse stock spilt vote May 19

1 · Reply

LemuelPitkin Apr. 24 at 8:30 PM

$SCYX

0 · Reply

Aurum81 Apr. 24 at 12:48 PM

$SCYX 10 days✅ Does this mean the Nasdaq requirements are met again?

1 · Reply

ImadogImaMut Apr. 24 at 11:03 AM

$SCYX Looks like April 1 , David converted warrants to shares So as of 3 weeks ago

1 · Reply

SnapCrackleStop Apr. 23 at 10:25 PM

$SCYX I am cautiously optimistic. The attack was feeble and we rose in the worst of market days. Some encouraging signs. We will see revenue from $GSK this year. I don’t see the stock declining below $1 significantly if at all. The shares are up from .69 and chart is telling us that more gains lie ahead. I think the reverse split will not be imposed or needed. The share count has no real affect on business performance. Trials continue pre funded through 2027 or longer. I think the stock is under accumulation by some big boys. The private placement/ warrant deal is going to benefit longstanding holders not shorts as warrant deals sometimes do. These institutional players are in for a multi bagger. Not just a double your money. No, this is something much greater. As mentioned….I am optimistic to say the least. $$$

1 · Reply

Biggiebag Apr. 23 at 9:15 PM

$SCYX must be a dream something good happened

0 · Reply

Market Cap	44.23M
Revenue (ttm)	20.60M
Net Income (ttm)	-8.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-41.80%
Debt to Equity Ratio	0.00

Volume	464,300
Avg Vol	603,554
Day's Range	N/A - N/A
Shares Out	44.66M
Stochastic %K	38%
Beta	1.12
Analysts	Strong Sell
Price Target	$3.47